Epidemiology

You have full text access to this OnlineOpen article

Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women†

  1. Annekatrin Lukanova1,2,
  2. Eva Lundin2,3,
  3. Andrea Micheli4,
  4. Alan Arslan5,6,7,
  5. Pietro Ferrari1,
  6. Sabina Rinaldi1,
  7. Vittorio Krogh4,
  8. Per Lenner8,
  9. Roy E. Shore6,7,
  10. Carine Biessy1,
  11. Paola Muti9,
  12. Elio Riboli1,
  13. Karen L. Koenig6,7,
  14. Mortimer Levitz5,6,
  15. Pär Stattin10,
  16. Franco Berrino4,
  17. Göran Hallmans2,
  18. Rudolf Kaaks1,
  19. Paolo Toniolo5,6,7,
  20. Anne Zeleniuch-Jacquotte6,7,‡,*

Article first published online: 21 OCT 2003

DOI: 10.1002/ijc.11529

Issue

International Journal of Cancer

International Journal of Cancer

Volume 108, Issue 3, pages 425–432, 20 January 2004

Additional Information

How to Cite

Lukanova, A., Lundin, E., Micheli, A., Arslan, A., Ferrari, P., Rinaldi, S., Krogh, V., Lenner, P., Shore, R. E., Biessy, C., Muti, P., Riboli, E., Koenig, K. L., Levitz, M., Stattin, P., Berrino, F., Hallmans, G., Kaaks, R., Toniolo, P. and Zeleniuch-Jacquotte, A. (2004), Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int. J. Cancer, 108: 425–432. doi: 10.1002/ijc.11529

Author Information

  1. 1

    International Agency for Research on Cancer, Lyon, France

  2. 2

    Department of Public Health and Clinical Medicine/Nutritional Research, Umeå University Hospital, Sweden

  3. 3

    Department of Medical Biosciences/Pathology, University of Umeå, Sweden

  4. 4

    Unit of Epidemiology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy

  5. 5

    Department of Obstetrics and Gynecology, New York University School of Medicine, New York, NY, USA

  6. 6

    New York University Cancer Institute, New York University School of Medicine, New York, USA

  7. 7

    Department of Environmental Medicine, New York University School of Medicine, New York, NY, USA

  8. 8

    Department of Oncology, Umeå University Hospital, Umeå, Sweden

  9. 9

    Department of Social & Preventive Medicine, State University of New York at Buffalo, School of Medicine & Biomedical Sciences, Buffalo, NY, USA

  10. 10

    Department of Urology and Andrology, Umeå University Hospital, Umeå, Sweden

  1. ‡

    Fax: +1-212-263-8570

*NYU Department of Environmental Medicine, 650 First Ave., Room 539, New York, NY 10016-3240

  1. †

    Contents of this study are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.

Publication History

  1. Issue published online: 21 NOV 2003
  2. Article first published online: 21 OCT 2003
  3. Manuscript Accepted: 23 JUL 2003
  4. Manuscript Revised: 10 JUL 2003
  5. Manuscript Received: 12 MAR 2003

Funded by

  • US National Cancer Institute. Grant Numbers: R01 CA81212-01, R01 CA81200-01, R01 CA34588, P30 CA16087
  • Swedish Cancer Society
  • Italian Association of Cancer Research

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (95K)

REFERENCES

  • 1
    Siiteri PK. Steroid hormones and endometrial cancer. Cancer Res 1978; 38: 4360–6.
  • 2
    Henderson BE, Ross RK, Pike MC, Casagande JT. Endogenous hormones as a major factor in human cancer. Cancer Res 1982; 42: 3232–9.
  • 3
    Key TJA, Pike MC. The dose-effect relationship between unopposed estrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer 1988; 57: 205–12.
  • 4
    Pike MC, Ross RK. Progestins and menopause: epidemiological studies of risk of endometrial and breast cancer. Steroids 2000; 65: 659–64.
  • 5
    Akhmedkhanov A, Zeleniuch-Jacquotte A, Toniolo P. Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives. Ann NY Acad Sci 2001; 943: 296–315.
    Direct Link:
  • 6
    Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev 2002; 11: 1531–43.
  • 7
    VainioH, BianchiniF, editors. Weight control and physical activity. Lyon, France: IARC Press, 2002.
  • 8
    Potischman N, Hoover RN, Brinton LA, Siiteri PK, Dorgan JF, Swanson CA, Berman ML, Mortel R, Twiggs LB, Barrett RJ, Wilbanks GD, Persky V, et al. Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst 1996; 88: 1127–35.
  • 9
    Legro RS, Kunselman AR, Miller SA, Satyaswaroop PG. Role of androgens in the growth of endometrial carcinoma: an in vivo animal model. Am J Obstet Gynecol 2001; 184: 303–8.
  • 10
    Tuckerman EM, Okon MA, Li T, Laird SM. Do androgens have a direct effect on endometrial function? An in vitro study. Fertil Steril 2000; 74: 771–9.
  • 11
    Hackenberg R, Schulz KD. Androgen receptor mediated growth control of breast cancer and endometrial cancer modulated by antiandrogen- and androgen-like steroids. J Steroid Biochem Mol Biol 1996; 56: 113–7.
  • 12
    Boman K, Strang P, Backstrom T, Stendahl U. The influence of progesterone and androgens on the growth of endometrial carcinoma. Cancer 1993; 71: 3565–9.
    Direct Link:
  • 13
    Yamamoto T, Kitawaki J, Urabe M, Honjo H, Tamura T, Noguchi T, Okada H, Sasaki H, Tada A, Terashima Y. Estrogen productivity of endometrium and endometrial cancer tissue; influence of aromatase on proliferation of endometrial cancer cells. J Steroid Biochem Mol Biol 1993; 44: 463–8.
  • 14
    Bulun SE, Noble LS, Takayama K, Michael MD, Agarwal V, Fisher C, Zhao Y, Hinshelwood MM, Ito Y, Simpson ER. Endocrine disorders associated with inappropriately high aromatase expression. J Steroid Biochem Mol Biol 1997; 61: 133–9.
  • 15
    Watanabe K, Sasano H, Harada N, Ozaki M, Niikura H, Sato S, Yajima A. Immunohistochemical, in situ hybridization, and biochemical studies. Am J Pathol 1995; 146: 491–500.
  • 16
    Yamaki J, Yamamoto T, Okada H. Aromatization of androstenedione by normal and neoplastic endometrium of the uterus. J Steroid Biochem 1985; 22: 63–6.
  • 17
    Austin H, Austin JM, Partridge EE, Hatch KD, Shingleton HM. Endometrial cancer, obesity and body fat distribution. Cancer Res 1991; 51: 568–72.
  • 18
    Zeleniuch-Jacquotte A, Akhmedkhanov A, Kato I, Koenig KL, Shore RE, Kim MY, Levitz M, Mittal KR, Raju U, Banerjee S, Toniolo P. Postmenopausal endogenous estrogens and risk of endometrial cancer: results of a prospective study. Br J Cancer 2001; 84: 975–81.
  • 19
    Toniolo P, Levitz M, Zeleniuch-Jacquotte A, Banerjee S, Koenig KL, Shore RE, Strax P, Pasternack BS. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 1995; 87: 190–7.
  • 20
    Berrino F, Muti P, Micheli, Bolelli G, Krogh V, Sciajno R, Pisani P, Panico S, Secreto G. Serum sex hormone levels after menopause and subsequent breast cancer. J Natl Cancer Inst 1996; 88: 291–6.
  • 21
    Palmqvist R, Hallmans G, Rinaldi S, Biessy C, Stenling R, Riboli E, Kaaks R. Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden. Gut 2002; 50: 642–6.
  • 22
    The Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002; 94: 606–16.
  • 23
    Rosner BA. A generalization of the paired t-test. Appl Stat 1982; 31: 9–13.
  • 24
    SAS Institute. SAS.STATR User's Guide Version 6. SAS manual 4(6). Cary, NC, USA: SAS Institute Inc., 1990.
  • 25
    Longcope C. Dehydroepiandrosterone metabolism. J Endocrinol 1996; 150: S125–7.
  • 26
    Ebeling P, Koivisto VA. Physiological importance of dehydroepiandrosterone. Lancet 1994; 343: 1479–81.
  • 27
    Boccuzzi G, Aragno M, Brignardello E, Tamagno E, Conti G, Di Monaco M, Racca S, Danni O, Di Carlo F. Opposite effects of dehydroepiandrosterone on the growth of 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinomas. Anticancer Res 1992; 12: 1479–83.
  • 28
    Seymour-Munn K, Adams J. Estrogenic effects of 5-androstene-3β, 17β-diol at physiological concentrations and its possible implication in the etiology of breast cancer. Endocrinol 1983; 112: 486–91.
  • 29
    Rinaldi S, Dechaud H, Biessy C, Morin-Raverot V, Toniolo P, Zeleniuch-Jacquotte A, Akhmedkhanov A, Shore RE, Secreto G, Ciampi A, Riboli E, Kaaks R. Reliability and validity of commercially available, direct radioimmunoassays for measurement of blood androgens and estrogens in postmenopausal women. Cancer Epidemiol Biomark Prev 2001; 10: 757–65.
  • 30
    Dorgan JF, Fears TR, McMahon RP, Aronson FL, Patterson BH, Greenhut SF. Measurement of steroid sex hormones in serum: a comparison of radioimmunoassay and mass spectometry. Steroids 2002; 67: 151–8.
View Full Article (HTML) Get PDF (95K)